Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 7Not yet recruiting 6Completed 4Withdrawn 2Terminated 1Recruiting 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Lymphoid 2Dermatologic 2Breast 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Glioma 1Ependymoma 1

Interventions

Temozolomide 80Radiotherapy 41Bevacizumab 35Radiosurgery 23Magnetic Resonance Spectroscopy 20Cyclophosphamide 17Radiation 14Irinotecan 13Carboplatin 12Topotecan 11Nivolumab 11Lomustine 11Filgrastim 10Everolimus 10Etoposide 10Erlotinib Hydrochloride 10pembrolizumab 9Radiotherapy, Intensity-Modulated 9Ipilimumab 9Granulocyte Colony-Stimulating Factor 8Carmustine 8antineoplaston AS 2-1 7antineoplaston A10 7Surgical Procedures, Operative 7Mental Status and Dementia Tests 7Isotretinoin 7Granulocyte-Macrophage Colony-Stimulating Factor 7sargramostim 6Vincristine 6TPI-287 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × AZD 6244 × CNS × Clear all
NCT03095248 2025-04-22

SEL-TH-1601

Children's Hospital Medical Center, Cincinnati

Phase 2 Terminated
10 enrolled 9 charts
CNS

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡